Small-molecule PROTAC mediates targeted protein degradation to treat STAT3-dependent epithelial cancer
Open Access
- 22 November 2022
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (22)
Abstract
The aberrant activation of STAT3 is associated with the etiology and progression in a variety of malignant epithelial-derived tumors, including head and neck squamous cell carcinoma (HNSCC) and colorectal cancer (CRC). Due to the lack of an enzymatic catalytic site or a ligand-binding pocket, there are no small-molecule inhibitors directly targeting STAT3 that have been approved for clinical translation. Emerging proteolysis targeting chimeric (PROTAC) technology–based approach represents a potential strategy to overcome the limitations of conventional inhibitors and inhibit activation of STAT3 and downstream genes. In this study, the heterobifunctional small-molecule–based PROTACs are successfully prepared from toosendanin (TSN), with 1 portion binding to STAT3 and the other portion binding to an E3 ubiquitin ligase. The optimized lead PROTAC (TSM-1) exhibits superior selectivity, potency, and robust antitumor effects in STAT3-dependent HNSCC and CRC — especially in clinically relevant patient-derived xenografts (PDX) and patient-derived organoids (PDO). The following mechanistic investigation identifies the reduced expression of critical downstream STAT3 effectors, through which TSM-1 promotes cell cycle arrest and apoptosis in tumor cells. These findings provide the first demonstration to our knowledge of a successful PROTAC-targeting strategy in STAT3-dependent epithelial cancer.Keywords
Funding Information
- National Natural Science Foundation of China (82173846,81903654)
- Shanghai Science and Technology Innovation Action Plan (21S11902800)
- Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (ZYYCXTD-D-202004)
- National key subject of drug innovation of China (2019ZX09201005-007)
- National key R & D program for key research project of modernization of traditional Chinese medicine (2019YFC1711602)
This publication has 62 references indexed in Scilit:
- Expression of activated signal transducer and activator of transcription-3 predicts poor prognosis in cervical squamous-cell carcinomaBritish Journal of Cancer, 2009
- Targeting STAT3 in cancer: how successful are we?Expert Opinion on Investigational Drugs, 2008
- Signal transducer and activator of transcription 3 activation is associated with bladder cancer cell growth and survivalMolecular Cancer, 2008
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Gene Expression Profiling Identifies Genes Predictive of Oral Squamous Cell CarcinomaCancer Epidemiology, Biomarkers & Prevention, 2008
- Roles of unphosphorylated STATs in signalingCell Research, 2008
- Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFκBGenes & Development, 2007
- Validating Stat3 in cancer therapyNature Medicine, 2005
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004
- Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesisOncogene, 2002